Results 151 to 160 of about 310,786 (327)

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Supplementary text_tables_figurelegends from Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

, 2023
Juliane Gust, Kevin A. Hay, Laïla‐Aïcha Hanafi, Daniel Li, David Myerson, Luis F. Gonzalez‐Cuyar, Cecilia C.S. Yeung, W. Conrad Liles, Mark M. Wurfel, José A. López, Junmei Chen, Dominic W. Chung, Susanna Harju-Baker, Tahsin Özpolat, Kathleen R. Fink, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle   +17 more
openalex   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

High-throughput screening for optimizing adoptive T cell therapies

Experimental Hematology & Oncology
Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non-
Yuchen Zhang, Qinglong Xu, Zhifei Gao, Honghao Zhang, Xiaoling Xie, Meifang Li   +5 more
doaj   +1 more source

Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy

Cell Reports
Summary: Adoptive cell therapies are emerging forms of immunotherapy that reprogram T cells for enhanced antitumor responses. Although surface programmed cell death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) engagement inhibits antitumor ...
Xinran Wang, Lu Lu, Xiaochuan Hong, Lingling Wu, Chao Yang, You Wang, Wenwen Li, Yuanqin Yang, Dongqing Cao, Wen Di, Liufu Deng   +10 more
doaj   +1 more source

A good start of immunotherapy in esophageal cancer

Cancer Medicine, 2019
Considering the benefits of immunotherapy in advanced melanoma, non–small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is ...
Qian Zhao, Jinming Yu, Xue Meng
doaj   +1 more source

O6.05 * ERBB2/HER2-SPECIFIC NATURAL KILLER CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA [PDF]

, 2014
M C Burger, C. Zhang, Lukas Jennewein, Kurt Schönfeld, Sabrina Genßler, Manuel Grez, Torsten Tonn, Michel Mittelbronn, J. P. Steinbach, Winfried S. Wels   +9 more
openalex   +1 more source

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

Advanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li   +6 more
wiley   +1 more source

Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction [PDF]

, 2003
William Ho, Joseph N. Blattman, Michelle L. Dossett, Cassian Yee, Philip D. Greenberg   +4 more
openalex   +1 more source

Engineered Mesenchymal Stem Cell–NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy

Advanced Science, EarlyView.
IL‐15‐engineered stem cell–NK cell complexes, assembled via bioorthogonal chemistry, enable effective lung cancer immunotherapy. Abstract Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation.
Qian Zhang, Bo Yin, Munaiwaier Sabier, Youlan Yang, Mengling Wu, Zhouping Zhao, Xuanzhi Luo, Yuehong Zhong, Xiuming Zhu, Jie Zhang, Jing Wang, Kai Chen, Fei Ruan, Wei Zhang, Zhimin Lu, Jiong Wang   +15 more
wiley   +1 more source